Hitachi gets EU cell manufacturing facilities with deal to buy Apceth Biopharma

Cell manufacturing CDMO Hitachi Chemical Advanced Therapeutics Solutions is picking up two cell therapy manufacturing facilities in Munich, Germany. (Apceth Biopharma)

Japan’s Hitachi, which is trying to forge a leadership position as a CDMO in regenerative and cell therapies, already has facilities in the U.S. Now it is making a move into Europe.

Hitachi Chemical Co. on Thursday announced its intent to pay €75.5 million ($86.8 million) for Apceth Biopharma, a contract manufacturer of cell and gene therapy products.

With the deal, the Japanese company picks up two manufacturing facilities in Munich, Germany with about 600 square meters (6,458 square feet) of cleanroom space. Hitachi said the facilities meet European regulations and the company already is doing work for both U.S. and European clients. The deal is slated to close in April.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Hitachi made a move into U.S. cell manufacturing 2016 when it agreed to pay $19.4 million for a nearly 20% stake in PCT, a subsidiary of Caladrius Biosciences, which has its own pipeline of cell therapy candidates. The deal also gave Hitachi access to two manufacturing facilities and a license to PCT's cell therapy technology for use in certain Asian countries, including Japan.

RELATED: Hitachi Chemical and PCT ink deal for licensing, manufacturing for cell therapy

PCT has a 25,000-square-foot cell therapy plant in Mountain View, California, and a 30,000-square-foot facility in Allendale, New Jersey, where Hitachi has its U.S. headquarters now.

Hitachi today said that it recently opened a facility in Yokohama, Japan, and that construction is underway for a third U.S. facility in Allendale that it says will provide commercial manufacturing capabilities once it opens in the second quarter of this year.

RELATED: Astellas jumps into gene and cell therapy production with $255M investment

Last fall, Hitachi signed a deal with GlaxoSmithKline to manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the U.S., Canadian and European trials.

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.